Due to availability of more potent antiretrovirals for HIV, there is a renewed interest in drug-sparing strategies, particularly two-drug regimens, to reduce long-term drug-related adverse effects and potentially lower health care costs. This presentation reviews the cost-effectiveness and roles of two-drug regimens as initial and maintenance HIV-1 therapy and provides relevant pharmacologic considerations, including drug-drug interactions and potential challenges.
Review clinical data that support the use of available two-drug antiretroviral regimens as initial and maintenance therapy
Examine the cost-effectiveness of two-drug antiretroviral regimens
Evaluate the roles of two-drug antiretroviral regimens and pharmacological considerations associated with each regimen
Jean Lee PharmD, Correct Rx Pharmacy Services, Inc.